Chronic obstructive pulmonary disease, or COPD in short, covers a group of lung conditions including chronic bronchitis and emphysema (shortness of breath), all marked by chronic inflammation of the air passages. There are several types of approved medications for COPD, such as Bronchodilators, Corticosteroids, Methylxanthines, Roflumilast, Mucoactive drugs, and Antibiotics. COPD is the third leading cause of death worldwide, affecting more than 390 million people globally.
The stock we are bringing to your attention today is that of Verona Pharma (VRNA), developing a groundbreaking COPD drug with a novel mechanism, marking the first major innovation in COPD treatment in over a decade.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.